Cargando…
Antiphospholipid antibodies in pulmonary embolism treated with direct oral anticoagulants: Prevalence data from unselected consecutive patients
BACKGROUND: Direct oral anticoagulants (DOACs) are the first-choice treatment option for the prevention of the recurrence of venous thrombosis in patients with pulmonary embolism (PE); however, their effect in patients with antiphospholipid syndrome (APS) is challenged. Therefore, the prevalence of...
Autores principales: | Justinussen, Tummas, Gram, Jorgen Brodersen, Bor, Mustafa Vakur |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9925606/ https://www.ncbi.nlm.nih.gov/pubmed/36798898 http://dx.doi.org/10.1016/j.rpth.2023.100050 |
Ejemplares similares
-
Lack of efficacy of direct oral anticoagulants compared to warfarin in antiphospholipid antibody syndrome
por: Giarretta, Igor, et al.
Publicado: (2022) -
Role of Direct Oral Anticoagulation Agents as Thromboprophylaxis in Antiphospholipid Syndrome
por: Arora, Shreya, et al.
Publicado: (2021) -
Antiphospholipid antibodies and anticoagulant therapy: capillaroscopic findings
por: Ferrari, Giorgia, et al.
Publicado: (2021) -
Direct oral anticoagulants in antiphospholipid syndrome with venous thromboembolism: Impact of the European Medicines Agency guidance
por: Fazili, Masarret, et al.
Publicado: (2019) -
Direct Oral Anticoagulants for Pulmonary Embolism: Importance of Anatomical Extent
por: Brekelmans, Marjolein P. A., et al.
Publicado: (2018)